The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation

Oncogene

Volumn 28, Issue 44, 2009, Pages 3903-3914

  Shah, K M ^a   Stewart, S E ^b   Wei, W ^a   Woodman, C B J ^a   O'Neil, J D ^a   Dawson, C W ^a   Young, L S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

EBV; Endosomes; Interferon; Lysosomes; NPC

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERFERON RECEPTOR; LATENT MEMBRANE PROTEIN 2; LUCIFERASE;

ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INNATE IMMUNITY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; VIRUS INFECTION;

CELL LINE; ENDOSOMES; EPITHELIAL CELLS; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; ONCOGENE PROTEINS, VIRAL; RECEPTORS, INTERFERON; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 70449110086     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.249     Document Type: Article

References (36)

1. Adachi K, Ichinose T, Takizawa N, Watanabe K, Kitazato K, Kobayashi N. (2007). Inhibition of betanodavirus infection by inhibitors of endosomal acidification. Arch Virol 152: 2217-2224.
2. Allen MD, Young LS, Dawson CW. (2005). The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol 79: 1789-1802.
3. Anderson LJ, Longnecker R. (2008a). An auto-regulatory loop for EBV LMP2A involves activation of Notch. Virology 371: 257-266.
4. Anderson LJ, Longnecker R. (2008b). Epstein Barr virus latent membrane protein 2A exploits Notch1 to alter B cell identity in vivo. Blood 113: 108-116.
5. Beadling C, Ng J, Babbage JW, Cantrell DA. (1996). Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. EMBO J 15: 1902-1913.
6. Cassady KA, Gross M. (2002). The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain. J Virol 76: 2029-2035.
7. Cho NH, Kingston D, Chang H, Kwon EK, Kim JM, Lee JH et al. (2006). Association of herpesvirus saimiri tip with lipid raft is essential for downregulation of T-cell receptor and CD4 coreceptor. J Virol 80: 108-118.
8. Claudinon J, Monier MN, Lamaze C. (2007). Interfering with interferon receptor sorting and trafficking: impact on signalling. Biochimie 89: 735-743.
9. Conrad M, Bubb VJ, Schlegel R. (1993). The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J Virol 67: 6170-6178.
10. Dawson CW, Eliopoulos AG, Blake SM, Barker R, Young LS. (2000). Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells. Virology 272: 204-217.
11. Dawson CW, George JH, Blake SM, Longnecker R, Young LS. (2001). The Epstein-Barr virus encoded latent membrane protein 2A augments signaling from latent membrane protein 1. Virology 289: 192-207. (Pubitemid 33140999)
12. Dykstra ML, Longnecker R, Pierce SK. (2001). Epstein-Barr virus coopts lipid rafts to block the signalling and antigen transport functions of the BCR. Immunity 14: 57-67.
13. Ikeda M, Longnecker R. (2007). Cholesterol is critical for Epstein-Barr virus latent membrane protein 2A trafficking and protein stability. Virology 360: 461-468. (Pubitemid 46482621)
14. Katze MG. (2002). Interferon, PKR, virology, and genomics: what is past and what is next in the new millennium? J Interferon Cytokine Res 22: 283-286.
15. Li Q, Means R, Lang S, Jung JU. (2007). Downregulation of gamma interferon receptor 1 by Kaposi's sarcoma-associated herpesvirus K3 and K5. J Virol 81: 2117-2127.
16. Liu J, Plotnikov A, Banerjee A, Suresh Kumar KG, Ragimbeau J, Marijanovic Z et al. (2008). Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem Biophys Res Commun 367: 388-393.
17. Longan L, Longnecker R. (2000). Epstein-Barr virus latent membrane protein 2A has no growth-altering effects when expressed in differentiating epithelia. J Gen Virol 81: 2245-2252.
18. Longnecker R. (2000). Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res 79: 175-200.
19. Mancao C, Hammerschmidt W. (2007). Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 110: 3715-3721.
20. Morrison JA, Klingelhutz AJ, Raab-Traub N. (2003). Epstein-Barr virus latent membrane protein 2A activates b-catenin signalling in epithelial cells. J Virol 77: 12276-12284.
21. Morrison TE, Mauser A, Wong A, Ting JP, Kenney SC. (2001). Inhibition of IFN-gamma signalling by an Epstein-Barr virus immediate-early protein. Immunity 15: 787-799.
22. Nanbo A, Takada K. (2002). The role of Epstein-Barr virus-encoded small RNAs (EBERs) in oncogenesis. Rev Med Virol 12: 321-326.
23. Offermann MK. (2007). Kaposi sarcoma herpesvirus-encoded inter-feron regulator factors. Curr Top Microbiol Immunol 312: 185-209.
24. Ogino T, Moriai S, Ishida Y, Ishii H, Katayama A, Miyokawa N et al. (2007). Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer 120: 2401-2410.
25. Raab-Traub N. (2002). Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12: 431-441.
26. Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, Pellegrini S. (2003). The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J 22: 537-547.
27. Randall RE, Goodbourn S. (2008). Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89: 1-47.
28. Rechsteiner MP, Berger C, Weber M, Sigrist JA, Nadal D, Bernasconi M. (2007). Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells. J Gen Virol 88: 1454-1459.
29. Rechsteiner MP, Berger C, Zauner L, Sigrist JA, Weber M, Longnecker R et al. (2008). Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection. J Virol 82: 1739-1747.
30. Rezaee SA, Cunningham C, Davison AJ, Blackbourn DJ. (2006). Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. J Gen Virol 87: 1781-1804.
31. Rovedo M, Longnecker R. (2007). Epstein-Barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol 81: 84-94. (Pubitemid 44975149)
32. Scholle F, Bendt KM, Raab-Traub N. (2000). Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74: 10681-10689.
33. Stewart S, Dawson CW, Takada K, Curnow J, Moody CA, Sixbey JW et al. (2004). Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc Natl Acad Sci USA 101: 15730-15735.
34. Tao Q, Chan AT. (2007). Nasopharyngeal carcinoma: molecular patho-genesis and therapeutic developments. Expert Rev Mol Med 9: 1-24.
35. Uozaki H, Fukayama M. (2008). Epstein-Barr virus and gastric carcinoma-viral carcinogenesis through epigenetic mechanisms. Int J Clin Exp Pathol 1: 198-216.
36. Young LS, Rickinson AB. (2004). Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.